MODY/LADA

“Avosentan reduces albuminuria when added to standard treatment in people with Type 2 diabetes and overt nephropathy but induces significant fluid overload and congestive heart failure,” the study authors write. “Of particular concern was a trend to a higher mortality with avosentan….

Increases in fasting plasma glucose during childhood — even though levels remain in the normal range 85-100mg/dL.) — can predict adult prediabetes and Type 2 diabetes later in life, a retrospective cohort study showed.…

Inherited genetic variations exist between whites and blacks living in the U.S., leading to less efficient metabolism of glucose and predisposition to diabetes in blacks.

Olmesartan reduced the risk of microalbuminuria by 23% in normoalbuminuric patients with Type 2 diabetes and at least one additional cardiovascular disease risk factor, results from a large European trial showed.

Sheri Colberg, Ph.D., FACSM, has been helping patients with diabetes successfully increase physical activity for many years and has written numerous books that patients and clinicians use. Most of her work recently has been about insulin and exercise, but many of you have written me to ask, “What about oral …

The study showed that “intensively lowering blood glucose to a target of 81 to 108 mg/dL does not benefit critically ill patients and may well increase their risk of…

The prevalence of metabolic syndrome is significantly higher in patients with type 2 diabetes than in those with autoimmune diabetes.

Slowing the heart rate with beta blockers in people with hypertension is associated with an increased risk of cardiovascular events and death, a new systematic review shows]. Furthermore, the slower the heart rate, the greater the risk.

Fenofibrate in combination with coenzyme Q10 (CoQ) appears to have a number of beneficial effects in type 2 diabetic subjects with mild left ventricular (LV) diastolic dysfunction, researchers report.

Study concludes that newly diagnosed never treated patients with type 2 diabetes without any cardiovascular risk factors show early manifestations of macrovascular disease.